

GIAPREZA® is the first and only human ANG II treatment—the only vasopressor designed to regulate the RAAS to help rapidly stabilize MAP in adults with septic shock or other distributive shock.^{1,2}

AVAILABLE IN 2 VIAL OPTIONS

2.5 mg/mL

Visit GIAPREZA.com for full safety and prescribing information.



0.5 mg/mL

FLEXIBLE AND EASILY TITRATABLE²

1. INITIATE

- The recommended starting dose of GIAPREZA is 20 ng/kg/min (0.02 mcg/kg/min)

2. ASSESS

- The median time to reach target MAP was 5 minutes
- The median dose of GIAPREZA was 10 ng/kg/min at 30 minutes

3. OPTIMIZE

- Titrate GIAPREZA as frequently as every 5 minutes by increments of up to 15 ng/kg/min as needed to achieve or maintain target blood pressure
- The half-life of GIAPREZA is less than 1 minute
- Once the underlying shock has sufficiently improved, down-titrate every 5 to 15 minutes in increments of up to 15 ng/kg/min, based on blood pressure

- > Doses as low as 1.25 ng/kg/min may be used
- > During the first 3 hours, the maximum dose should not exceed 80 ng/kg/min
- > Maintenance dose should not exceed 40 ng/kg/min

ADMINISTRATION



Administer GIAPREZA via continuous intravenous infusion



Administration through a central venous line is recommended



Monitor blood pressure closely after GIAPREZA initiation

ANG=angiotensin; MAP=mean arterial pressure; RAAS=renin-angiotensin-aldosterone system.

SELECTED IMPORTANT SAFETY INFORMATION

Indication

GIAPREZA® (angiotensin II) increases blood pressure in adults with septic or other distributive shock.

Contraindications

None.

Warnings and Precautions

The safety of GIAPREZA was evaluated in 321 adults with septic or other distributive shock in a randomized, double-blind, placebo-controlled study, ATHOS-3. There was a higher incidence of arterial and venous thrombotic and thromboembolic events in patients who received GIAPREZA compared to placebo-treated patients in the ATHOS-3 study (13% vs. 5%). The major imbalance was in deep venous thromboses. Use concurrent venous thromboembolism (VTE) prophylaxis.

Please see additional Important Safety Information on the next page. Before administering, please see the Full Prescribing Information for GIAPREZA.

SUPPLY, STORAGE, AND PREPARATION



SUPPLY

GIAPREZA® (angiotensin II) injection is a clear, aqueous solution supplied in a carton with a 1-mL single-dose vial containing 0.5 or 2.5 mg/mL angiotensin II as a sterile liquid.

STORAGE

GIAPREZA vials should be stored in the refrigerator between 2 °C to 8 °C (36 °F to 46 °F).

Diluted solution may be stored at room temperature or under refrigeration for up to 24 hours, after which it should be discarded.

Discard vial and any unused portion of the drug product after use.

PREPARATION

Inspect for particulate matter and discoloration prior to administration.

Dilute the appropriate amount of GIAPREZA in a normal saline (0.9% sodium chloride) infusion bag to achieve the desired final concentration of 5,000 ng/mL or 10,000 ng/mL.

Remember that GIAPREZA dosage is measured in nanograms (ng), not micrograms (mcg).

Learn more about how GIAPREZA can rapidly stabilize MAP to help save lives at [GIAPREZA.com](https://www.giapreza.com)

SELECTED IMPORTANT SAFETY INFORMATION

Adverse Reactions

The most common adverse reactions reported in greater than 10% of GIAPREZA-treated patients were thromboembolic events. Adverse reactions occurring in $\geq 4\%$ of patients treated with GIAPREZA and $\geq 1.5\%$ more often than placebo-treated patients in the ATHOS-3 study were thromboembolic events (including deep vein thrombosis), thrombocytopenia, tachycardia, fungal infection, delirium, acidosis, hyperglycemia, and peripheral ischemia.

Drug Interactions

Angiotensin converting enzyme (ACE) inhibitors may increase response to GIAPREZA. Angiotensin II receptor blockers (ARBs) may reduce response to GIAPREZA.

You are encouraged to report negative side effects of prescription drugs to the FDA.

To report SUSPECTED ADVERSE REACTIONS, please contact:

La Jolla Pharmaceutical Company
1-800-651-3861 | medicalinformation@ljpc.com

U.S. Food and Drug Administration
1-800-FDA-1088 | www.fda.gov/medwatch

Please see additional Important Safety Information for GIAPREZA on the previous page. Before administering, please see the [Full Prescribing Information for GIAPREZA](#).

References: 1. National Center for Biotechnology Information. PubChem Compound Summary for CID 172198, angiotensin II. Accessed December 3, 2025. <https://pubchem.ncbi.nlm.nih.gov/compound/Angiotensin-II-human> 2. GIAPREZA. Prescribing information. La Jolla Pharmaceutical Company; 2021.